BMS, QIMR Form Immuno-Oncology PactBy
Bristol-Myers Squibb and the QIMR Berghofer Medical Research Institute, a translational research institute focused on cancer, infectious diseases, and mental health have signed a research collaboration and license agreement to discover therapeutic antibodies against an undisclosed immuno-oncology (I-O) target.
Bristol-Myers Squibb will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration. Financial terms were not disclosed.
Source: Bristol-Myers Squibb